OncoPharm

Thought on:

Double Dauno, but they said it better --> (https://open.spotify.com/episode/0eHEl3bUdZdg3mynUiNMG6?si=88cdab4b882e4667)

Blinatumumab FTW

The end of "the" neutropenic diet?

Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice.

Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1).

A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.

Recent voluntary withdrawals from the US market of belantamab-mafodotin and atezolizumab's indication for bladder cancer have us weighing (again) the pros & cons of the accelerated approval program.

Also, FDA approves the 1st fecal transplant product.

A new antibody-drug conjugate is approved for ovarian cancer.

We review the 5-year update of CheckMate 227 and the POSEIDON to generate the hypothesis that CLTA-4 inhibition has a role in PD-L1 negative metastatic NSCLC.

CM 227 update: https://pubmed.ncbi.nlm.nih.gov/?term=36223558

POSEIDON: https://pubmed.ncbi.nlm.nih.gov/?term=36327426

Editorial: https://pubmed.ncbi.nlm.nih.gov/?term=36331243

The International Nonproprietary Names (INN) unit from WHO decided to drop the -mab suffix from new drug names. Instead, -tug, -bart, -ment, and -mig will be used. We have some thoughts.

INN Report: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122354/#

New Drug Approvals!

-Tremelimumab, the 2nd CTLA-4 inhibitor, finally gets approved.

-Teclistamab, an excited BCMA-CD3 T-cell engager for multiple myeloma.

Landmarks of OncoPharm episode on maintenance pemetrexed in NSCLC.

Switch maintenance: https://doi.org/10.1016/s0140-6736(09)61497-5

Continuation maintenance (PARAMOUNT): https://doi.org/10.1016/S1470-2045(12)70063-3

We discuss a phase I study (CALM) of an allogeneic anti-CD19 CART-T product, using aprepitant (?) for pruritis from EGFR TKIs, and the widely discussed NordICC study on colonoscopy screening.

CALM: https://doi.org/10.1016/S2352-3026(22)00245-9

Aprepitant vs. desloratidine: https://doi.org/10.1002/cncr.34474

NordICC: https://www.nejm.org/doi/full/10.1056/NEJMoa2208375

NordICC editorial: https://www.nejm.org/doi/full/10.1056/NEJMe2211595

A new FGFR inhibitor, futibatinib, is approved.

Is ESR1 mutation monitoring the next thing in HR+ metastatic breast cancer? The PADA-1 trial offers insight.

What the heck is GPRC5D (rhymes with CAR-T)?

PADA-1: https://doi.org/10.1016/S1470-2045(22)00555-1

GPRC5D CAR-T in Myeloma: https://www.nejm.org/doi/full/10.1056/NEJMoa2209900